|
Through the agreement, Piramal Critical Care will co-promote two of Cumberland's branded hospital products, Caldolor® and Vaprisol® throughout the United States. Piramal will help expand Cumberland's reach for these products by providing coverage to an additional group of hospitals where Piramal's critical care sales force has existing relationships. Cumberland will maintain its promotional efforts supporting the products and continue its focus on a select group of medical centers across the U.S. through its hospital sales force. Cumberland will also continue to provide the marketing, national accounts, distribution, and medical support for the brands. The multi-year collaboration will provide expanded sales promotion for the two brands, increased communication to medical professionals, and enhanced availability of the products to support patient care throughout the U.S.
Piramal Critical Care is a leader in the field of anesthesia. Piramal has a professional critical care sales organization and commercial capabilities with global reach. Piramal's consistent efforts and commitment towards the critical care network have allowed them to quickly expand their success in the U.S. and across the world.
A.J. Kazimi, CEO – Cumberland Pharmaceuticals said: "We welcome Piramal as a co-promotion partner in the U.S. and believe this new collaboration will enhance Cumberland's ability to further advance patient care through the delivery of high quality pharmaceutical products in this country."
Peter DeYoung, CEO - Piramal Critical Care said: "We are pleased to partner with Cumberland to co-promote Caldolor® and Vaprisol® in the United States. With the addition of these important products, we will be able to significantly enhance our offering of critical care solutions which we provide to our valued customers and patients."
|